Follow Us
https://www.thebody.com/category/non-hiv-stis/tag/news-analysis

The Latest

doctor closing office

Three STDs Are at an All-Time High. And Not Because of PrEP or More Risky Sex

While many people want to blame more risky sex and less condom use on the age of PrEP, the real reasons STDs are rising may have more to do with decreasing resources and programs to fight them.

First Nations Bilingual stop sign in Canada

Canada's Historic Syphilis Outbreak Is Even Worse for Its Under-Resourced Indigenous Population

Indigenous people in the northern region of Alberta, Canada, face increased health risks from injection drug use, syphilis, and HIV.

The Low Cost of Universal Access Img

The Low Cost of Universal Access

"Generic treatments for HIV, viral hepatitis, and cancer can be affordably -- and profitably -- mass-produced for broad, unobstructed availability," writes Tracy Swan in this interview with Andrew Hill.

Hedge Fund Billionaires Are New Target for Hepatitis C Cure Protests Img

Hedge Fund Billionaires Are New Target for Hepatitis C Cure Protests

The high cost of hepatitis C treatment has inspired lawsuits and protests. Now, activist have targeted the hedge fund investors who they say are reaping profits from the pricey pills. Rod McCullom reports.

As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math Img

As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math

How does pharmaceutical company math work? One activist takes Gilead to task for the price of its next hepatitis C drug.

The Cure for Hepatitis C, Withheld Img

The Cure for Hepatitis C, Withheld

In just the past month, a pair of drugs were approved that may forever change (for the better!) the way hepatitis C is treated. But as treatment advocate George Carter laments, the revolution may come at too high a price.

Promo Image

Activists Condemn Gilead for Exorbitant Price of Its New Hepatitis C Drug

The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir), a once-daily, first-in-class nucleotide polymerase inhibitor approved by the U.S. Food and Drug Administra...